Cited 0 times in Scipus Cited Count

Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer

DC Field Value Language
dc.contributor.authorKim, H-
dc.contributor.authorKim, S-
dc.contributor.authorChoi, S-
dc.contributor.authorPark, C-
dc.contributor.authorPark, S-
dc.contributor.authorPereira, S-
dc.contributor.authorMa, M-
dc.contributor.authorYoo, D-
dc.contributor.authorPaeng, K-
dc.contributor.authorJung, W-
dc.contributor.authorPark, S-
dc.contributor.authorOck, CY-
dc.contributor.authorLee, SH-
dc.contributor.authorChoi, YL-
dc.contributor.authorChung, JH-
dc.date.accessioned2024-09-27T00:19:45Z-
dc.date.available2024-09-27T00:19:45Z-
dc.date.issued2024-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/32800-
dc.description.abstractPURPOSEEvaluation of PD-L1 tumor proportion score (TPS) by pathologists has been very impactful but is limited by factors such as intraobserver/interobserver bias and intratumor heterogeneity. We developed an artificial intelligence (AI)-powered analyzer to assess TPS for the prediction of immune checkpoint inhibitor (ICI) response in advanced non-small cell lung cancer (NSCLC).MATERIALS AND METHODSThe AI analyzer was trained with 393,565 tumor cells annotated by board-certified pathologists for PD-L1 expression in 802 whole-slide images (WSIs) stained by 22C3 pharmDx immunohistochemistry. The clinical performance of the analyzer was validated in an external cohort of 430 WSIs from patients with NSCLC. Three pathologists performed annotations of this external cohort, and their consensus TPS was compared with AI-based TPS.RESULTSIn comparing PD-L1 TPS assessed by AI analyzer and by pathologists, a significant positive correlation was observed (Spearman coefficient = 0.925; P <.001). The concordance of TPS between AI analyzer and pathologists according to TPS ≥50%, 1%-49%, and <1% was 85.7%, 89.3%, and 52.4%, respectively. In median progression-free survival (PFS), AI-based TPS predicted prognosis in the TPS 1%-49% or TPS <1% group better than the pathologist's reading, with the TPS ≥50% group as a reference (hazard ratio [HR], 1.49 [95% CI, 1.19 to 1.86] v HR, 1.36 [95% CI, 1.08 to 1.71] for TPS 1%-49% group, and HR, 2.38 [95% CI, 1.69 to 3.35] v HR, 1.62 [95% CI, 1.23 to 2.13] for TPS <1% group).CONCLUSIONPD-L1 TPS assessed by AI analyzer correlates with that of pathologists, with clinical performance also being comparable when referenced to PFS. The AI model can accurately predict tumor response and PFS of ICI in advanced NSCLC via assessment of PD-L1 TPS.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHArtificial Intelligence-
dc.subject.MESHB7-H1 Antigen-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHImmune Checkpoint Inhibitors-
dc.subject.MESHLung Neoplasms-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.titleClinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer-
dc.typeArticle-
dc.identifier.pmid38723233-
dc.identifier.urlhttps://ascopubs.org/doi/pdf/10.1200/PO.23.00556-
dc.contributor.affiliatedAuthorKim, S-
dc.type.localJournal Papers-
dc.identifier.doi10.1200/PO.23.00556-
dc.citation.titleJCO precision oncology-
dc.citation.volume8-
dc.citation.date2024-
dc.citation.startPagee2300556-
dc.citation.endPagee2300556-
dc.identifier.bibliographicCitationJCO precision oncology, 8. : e2300556-e2300556, 2024-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn2473-4284-
dc.relation.journalidJ024734284-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse